Cargando…
Rationale and design of the “Tocilizumab in patients with moderate to severe COVID-19: an open-label multicentre randomized controlled” trial (TOCIBRAS)
INTRODUCTION: Pro-inflammatory markers play a significant role in the disease severity of patients with COVID-19. Thus, anti-inflammatory therapies are attractive agents for potentially combating the uncontrolled inflammatory cascade in these patients. We designed a trial testing tocilizumab versus...
Autores principales: | de Farias, Danielle Leão Cordeiro, Prats, João, Cavalcanti, Alexandre Biasi, Rosa, Regis Goulart, Machado, Flávia Ribeiro, Berwanger, Otávio, de Azevedo, Luciano César Pontes, Lopes, Renato Delascio, Avezum, Álvaro, Kawano-Dourado, Leticia, Damiani, Lucas Petri, Rojas, Salomón Soriano Ordinola, de Oliveira, Cleyton Zanardo, Andrade, Luis Eduardo Coelho, Sandes, Alex Freire, Pintão, Maria Carolina, de Castro Júnior, Claudio Galvão, Scheinberg, Phillip, Veiga, Viviane Cordeiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Associação de Medicina Intensiva Brasileira - AMIB
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595725/ https://www.ncbi.nlm.nih.gov/pubmed/32965395 http://dx.doi.org/10.5935/0103-507X.20200060 |
Ejemplares similares
-
Thromboembolic and bleeding events in intensive care unit patients with COVID-19: results from a Brazilian tertiary hospital
por: Brandão, Antonio Adolfo Guerra Soares, et al.
Publicado: (2021) -
Hidroxicloroquina para Pacientes com COVID-19 não Hospitalizados: Uma Revisão Sistemática e Metanálise de Ensaios Clínicos Randomizados
por: Lucchetta, Rosa, et al.
Publicado: (2023) -
Adverse events during intrahospital transport of critically ill
patients in a large hospital
por: Veiga, Viviane Cordeiro, et al.
Publicado: (2019) -
COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomized trial
por: Tomazini, Bruno Martins, et al.
Publicado: (2020) -
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
por: Veiga, Viviane C, et al.
Publicado: (2021)